Skip to main content
STIM
NASDAQ Industrial Applications And Services

Neuronetics Reports 99% Revenue Growth Driven by Acquisition, Faces Margin Pressure, Debt Covenant Waivers, and CEO Transition

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
8
Price
$1.5
Mkt Cap
$93.141M
52W Low
$1.17
52W High
$5.34
Market data snapshot near publication time

summarizeSummary

Neuronetics reported 99% revenue growth in 2025, driven by the Greenbrook acquisition, but saw gross margins decline. The company continues to incur losses, secured debt covenant waivers, and announced a new CEO amidst ongoing legal investigations and a major shareholder's plan to sell shares.


check_boxKey Events

  • Strong Revenue Growth Driven by Acquisition

    Total revenues increased by 99% to $149.2 million for the year ended December 31, 2025, up from $74.9 million in 2024. This growth was primarily attributable to the acquisition of Greenbrook in December 2024, which significantly shifted the U.S. revenue mix, with clinic revenue now representing 59% of U.S. revenues compared to 6% in the prior year.

  • Reduced Net Loss Amidst Significant Margin Compression

    The company reported a net loss of $39.1 million for 2025, an improvement from a $43.7 million net loss in 2024. However, gross margin decreased substantially to 48.5% in 2025 from 72.3% in 2024, primarily due to the inclusion of Greenbrook's clinic business and a reduction in treatment session revenue.

  • Debt Covenant Waivers and Principal Payment

    On March 12, 2026, Neuronetics amended its Perceptive Credit Facility to modify revenue and liquidity covenants and made a one-time principal payment of $5.0 million. Critically, the Administrative Agent and Majority Lender waived compliance with the 'No Qualification Requirement' regarding 'going concern' language for financial statements covering fiscal year 2025 and periods within 2026.

  • Executive Leadership Transition

    Daniel L. Reuvers has been appointed as the new President and Chief Executive Officer, effective March 23, 2026, succeeding Keith J. Sullivan, who will retire on March 31, 2026. Mr. Reuvers will receive an initial annual base salary of $730,000 and a grant of 1,500,000 restricted stock units.


auto_awesomeAnalysis

Neuronetics' annual report reveals substantial revenue growth in 2025, primarily due to the Greenbrook acquisition, but this came with a significant reduction in gross margins. The company continues to operate at a net loss and relies on dilutive equity financing and debt amendments to manage its liquidity. The waiver of 'going concern' language for 2025 and 2026 financial statements, along with ongoing legal investigations, highlights persistent financial and operational challenges. The change in CEO and a major shareholder's intent to sell shares add further uncertainty.

At the time of this filing, STIM was trading at $1.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $93.1M. The 52-week trading range was $1.17 to $5.34. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed STIM - Latest Insights

STIM
Apr 13, 2026, 8:32 AM EDT
Source: GlobeNewswire
Importance Score:
8
STIM
Apr 09, 2026, 4:02 PM EDT
Filing Type: DEF 14A
Importance Score:
9
STIM
Apr 08, 2026, 9:17 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
STIM
Apr 06, 2026, 4:51 PM EDT
Source: Reuters
Importance Score:
7
STIM
Apr 06, 2026, 4:40 PM EDT
Filing Type: 8-K
Importance Score:
7
STIM
Apr 06, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
STIM
Mar 31, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
STIM
Mar 30, 2026, 7:41 PM EDT
Filing Type: 4
Importance Score:
7
STIM
Mar 30, 2026, 9:37 AM EDT
Filing Type: 4
Importance Score:
7
STIM
Mar 20, 2026, 8:51 AM EDT
Filing Type: 4
Importance Score:
8